365 related articles for article (PubMed ID: 31382521)
1. Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.
Kornmueller K; Vidakovic I; Prassl R
Molecules; 2019 Aug; 24(15):. PubMed ID: 31382521
[TBL] [Abstract][Full Text] [Related]
2. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.
Kuai R; Li D; Chen YE; Moon JJ; Schwendeman A
ACS Nano; 2016 Mar; 10(3):3015-41. PubMed ID: 26889958
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional changes in high-density lipoprotein induced by chemical modification.
Murakami T; Okamoto H; Kim H
Biomater Sci; 2015 May; 3(5):712-5. PubMed ID: 26222589
[TBL] [Abstract][Full Text] [Related]
4. Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: A New Paradigm for Drug Discovery.
Huang J; Wang D; Huang LH; Huang H
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979310
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein-biomimetic nanocarriers for glioblastoma-targeting delivery: the effect of shape.
Huang JL; Jiang G; Song QX; Gu X; Song HH; Wang XL; Jiang D; Kang T; Feng XY; Jiang XG; Chen HZ; Gao XL
Pharmazie; 2016 Dec; 71(12):709-714. PubMed ID: 29441999
[TBL] [Abstract][Full Text] [Related]
6. Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.
Raut S; Garud A; Nagarajan B; Sabnis N; Remaley A; Fudala R; Gryczynski I; Gryczynski Z; Dzyuba SV; Borejdo J; Lacko A
J Pharmacol Exp Ther; 2020 Apr; 373(1):113-121. PubMed ID: 31941718
[TBL] [Abstract][Full Text] [Related]
7. HDL and Therapy.
Li K; Xie X; Guo Y
Adv Exp Med Biol; 2022; 1377():171-187. PubMed ID: 35575930
[TBL] [Abstract][Full Text] [Related]
8. Sterically stabilized recombined HDL composed of modified apolipoprotein A-I for efficient targeting toward glioma cells.
Li J; Han M; Li J; Ge Z; Wang Q; Zhou K; Yin X
Drug Deliv; 2020 Dec; 27(1):530-541. PubMed ID: 32241173
[TBL] [Abstract][Full Text] [Related]
9. Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications.
Aranda-Lara L; Isaac-Olivé K; Ocampo-García B; Ferro-Flores G; González-Romero C; Mercado-López A; García-Marín R; Santos-Cuevas C; Estrada JA; Morales-Avila E
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296638
[TBL] [Abstract][Full Text] [Related]
10. Reconstituted HDL as a therapeutic delivery device.
Fox CA; Moschetti A; Ryan RO
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Nov; 1866(11):159025. PubMed ID: 34375767
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional Dextran Sulfate-Coated Reconstituted High Density Lipoproteins Target Macrophages and Promote Beneficial Antiatherosclerotic Mechanisms.
Zhao Y; Jiang C; He J; Guo Q; Lu J; Yang Y; Zhang W; Liu J
Bioconjug Chem; 2017 Feb; 28(2):438-448. PubMed ID: 28004910
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein AI tertiary structures determine stability and phospholipid-binding activity of discoidal high-density lipoprotein particles of different sizes.
Chen B; Ren X; Neville T; Jerome WG; Hoyt DW; Sparks D; Ren G; Wang J
Protein Sci; 2009 May; 18(5):921-35. PubMed ID: 19384992
[TBL] [Abstract][Full Text] [Related]
13. Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin.
Zhang X; Chen B
Cancer Lett; 2010 Dec; 298(1):26-33. PubMed ID: 20579804
[TBL] [Abstract][Full Text] [Related]
14. The Composition of Reconstituted High-Density Lipoproteins (rHDL) Dictates the Degree of rHDL Cargo- and Size-Remodeling via Direct Interactions with Endogenous Lipoproteins.
Pedersbæk D; Kræmer MK; Kempen PJ; Ashley J; Braesch-Andersen S; Andresen TL; Simonsen JB
Bioconjug Chem; 2019 Oct; 30(10):2634-2646. PubMed ID: 31487985
[TBL] [Abstract][Full Text] [Related]
15. Detecting the functional complexities between high-density lipoprotein mimetics.
Sei YJ; Ahn J; Kim T; Shin E; Santiago-Lopez AJ; Jang SS; Jeon NL; Jang YC; Kim Y
Biomaterials; 2018 Jul; 170():58-69. PubMed ID: 29653287
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
17. Lipoproteins for therapeutic delivery: recent advances and future opportunities.
Raut S; Dasseux JL; Sabnis NA; Mooberry L; Lacko A
Ther Deliv; 2018 Mar; 9(4):257-268. PubMed ID: 29495929
[TBL] [Abstract][Full Text] [Related]
18. Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA.
Rui M; Tang H; Li Y; Wei X; Xu Y
Pharm Res; 2013 May; 30(5):1203-14. PubMed ID: 23242841
[TBL] [Abstract][Full Text] [Related]
19. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.
Lyssenko NN; Nickel M; Tang C; Phillips MC
FASEB J; 2013 Jul; 27(7):2880-92. PubMed ID: 23543682
[TBL] [Abstract][Full Text] [Related]
20. Formation of spherical, reconstituted high density lipoproteins containing both apolipoproteins A-I and A-II is mediated by lecithin:cholesterol acyltransferase.
Clay MA; Pyle DH; Rye KA; Barter PJ
J Biol Chem; 2000 Mar; 275(12):9019-25. PubMed ID: 10722751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
